Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?
A study found that “pacritinib may offer a unique survival advantage” for patients with myelofibrosis (MF) and thrombocytopenia who achieve any spleen volume reduction (SVR). The study was led by Helen Ajufo, MD, of Washington University School of Medicine in St. Louis, Missouri, and published in the European Journal of Haematology. Previous retrospective analyses have tied SVR to improved overall survival (OS) in patients treated with ruxolitinib with platelets >100 × 109/L. This post-hoc landmark analysis sought to assess the connection between SVR and pacritinib versus best available therapy (BAT), including ruxolitinib, in patients with MF with platelets ≤100 × 109/L. The researchers utilized a cohort from the randomized, controlled, multicenter, phase 3 PERSIST-2 study. Included patients received pacritinib 200 mg twice daily (n=89) or BAT (n=84; 39 received ruxolitinib). The following SVR thresholds were used to define responders and nonresponders: • ≥35% • ≥20% • ≥10% • >0% Most
